Therapeutic efficacy of ABT-737, a selective inhibitor of BCL-2, in small cell lung cancer
about
A primary xenograft model of small-cell lung cancer reveals irreversible changes in gene expression imposed by culture in vitroTargeting Cell Survival Proteins for Cancer Cell DeathTreatment Strategies that Enhance the Efficacy and Selectivity of Mitochondria-Targeted Anticancer AgentsTargeting BCL2-Proteins for the Treatment of Solid TumoursTargeting the Bcl-2 family for cancer therapyTargeting Mcl-1 for the therapy of cancerBh3 induced conformational changes in Bcl-Xl revealed by crystal structure and comparative analysisEfficient elimination of cancer cells by deoxyglucose-ABT-263/737 combination therapyUpregulating Noxa by ER stress, celastrol exerts synergistic anti-cancer activity in combination with ABT-737 in human hepatocellular carcinoma cellsProteasomal degradation of Mcl-1 by maritoclax induces apoptosis and enhances the efficacy of ABT-737 in melanoma cellsBM-1197: a novel and specific Bcl-2/Bcl-xL inhibitor inducing complete and long-lasting tumor regression in vivoIncorporating network structure in integrative analysis of cancer prognosis data.Phase I study of Navitoclax (ABT-263), a novel Bcl-2 family inhibitor, in patients with small-cell lung cancer and other solid tumors.Phase II study of single-agent navitoclax (ABT-263) and biomarker correlates in patients with relapsed small cell lung cancer.Nanoencapsulation of ABT-737 and camptothecin enhances their clinical potential through synergistic antitumor effects and reduction of systemic toxicity.Achaete-scute complex homologue 1 regulates tumor-initiating capacity in human small cell lung cancer.Array comparative genomic hybridization-based characterization of genetic alterations in pulmonary neuroendocrine tumors.Genomic characterisation of small cell lung cancer patient-derived xenografts generated from endobronchial ultrasound-guided transbronchial needle aspiration specimens.From laptop to benchtop to bedside: structure-based drug design on protein targets.Bcl-2 and β1-integrin predict survival in a tissue microarray of small cell lung cancerASCL1 is a lineage oncogene providing therapeutic targets for high-grade neuroendocrine lung cancers.Overcoming multiple drug resistance mechanisms in medulloblastoma.Cafestol overcomes ABT-737 resistance in Mcl-1-overexpressed renal carcinoma Caki cells through downregulation of Mcl-1 expression and upregulation of Bim expression.Optimization of circulating biomarkers of obatoclax-induced cell death in patients with small cell lung cancer.Novel small-molecule inhibitors of Bcl-XL to treat lung cancer.Small-cell lung cancer-associated autoantibodies: potential applications to cancer diagnosis, early detection, and therapy.Targeted therapies in small cell lung cancer: a reviewDistribution of Bim determines Mcl-1 dependence or codependence with Bcl-xL/Bcl-2 in Mcl-1-expressing myeloma cells.Assessment of ABT-263 activity across a cancer cell line collection leads to a potent combination therapy for small-cell lung cancer.An antiapoptotic BCL-2 family expression index predicts the response of chronic lymphocytic leukemia to ABT-737.Role of p38 MAPK in enhanced human cancer cells killing by the combination of aspirin and ABT-737.Binding of TS1, an anti-keratin 8 antibody, in small-cell lung cancer after 177Lu-DOTA-Tyr3-octreotate treatment: a histological study in xenografted mice.Sensitization of BCL-2-expressing breast tumors to chemotherapy by the BH3 mimetic ABT-737Rapamycin rescues ABT-737 efficacy in small cell lung cancerRadiosensitization by a novel Bcl-2 and Bcl-XL inhibitor S44563 in small-cell lung cancer.Small Cell Lung Cancer Screen of Oncology Drugs, Investigational Agents, and Gene and microRNA Expression.Bcl-2, Bcl-x(L), and Bcl-w are not equivalent targets of ABT-737 and navitoclax (ABT-263) in lymphoid and leukemic cellsNovel therapeutic approaches for small cell lung cancer: the future has arrivedCucurbitacin-I inhibits Aurora kinase A, Aurora kinase B and survivin, induces defects in cell cycle progression and promotes ABT-737-induced cell death in a caspase-independent manner in malignant human glioma cellsCombination treatments with ABT-263 and an immunotoxin produce synergistic killing of ABT-263-resistant small cell lung cancer cell lines.
P2860
Q24647698-A402EFBD-4915-41CB-AA2E-AA83CF11CE84Q26765447-075C4E5B-C0D0-4FD9-9130-08D52ECDA323Q26800890-0904E2DE-0AD2-42A8-B55C-D77A4BBC6828Q26853686-0438692B-4C2A-4B1C-ADF5-F1D828A6BEF3Q26866936-9195DD67-20C3-4BFA-9B3D-8F02D01DF34DQ27011870-832C05CF-3790-4AB8-A25F-B6C0056C54EBQ27700247-E7DFB8E9-2D0D-4336-B953-D8DA48DEAB6CQ28477131-B411C9E2-1F4F-4A09-B835-0BB6488F6A2EQ28484487-B5D66CFD-0C35-4F48-BE7F-80BD552AF3D3Q28534817-5A7CA26F-0A8E-4A92-A3C5-4C5EFC463F24Q28539452-A70C759C-8536-4702-9426-A30E61B3E76FQ30577859-07F5F042-292B-4892-9834-1371A3C08540Q33393931-6C3BBBA4-5756-4F3F-B11F-71FDD5F0D169Q33400716-17BAE746-341F-4911-81D0-B8D4172534E3Q33418086-C818D4CD-BB82-4AF6-ABB4-DDB74B21D62AQ34056677-06F38996-E365-4985-A0B9-4C8BC75178AAQ34059518-A006BA3C-2E58-4E89-B69A-2BF2D29A3579Q34142556-C6973A52-8783-4457-AC63-489442185F59Q34153589-99007A67-38EB-4306-B048-812B8A0E7428Q34363479-9C5E1B47-46CE-4E58-9146-43741EB304C8Q34383742-973313B7-B1FF-4478-A550-D36E94245D5DQ34500602-79BC5774-470C-4EB7-8BD1-B7FF64D1FE92Q34662207-5C8263CA-6B3F-4B73-887F-13DC935B41BAQ34763661-9A327DF1-FB16-4477-AA1E-0E40B4896568Q34793542-10746F3A-008C-485A-95E1-648147A1F8FFQ34826137-1A8155DC-3E44-4FCD-90E5-6853B2E20E45Q35076234-982F43C5-3DD6-4937-A760-C0783494C3DCQ35153790-73B27935-AE63-4ABF-B43C-D739C79A31DDQ35212727-50B5E3D5-349E-4190-87B9-35763F4CBB7AQ35266213-454F3AFE-B5D5-458D-9935-A5AF5960ECD4Q35531406-61222668-145C-4B59-B932-426B0089C59CQ35731542-A51E0BC7-5C44-4456-97FA-798B7F4F3D59Q35779325-50A557EA-3E38-48E7-8B01-2791808294E4Q35878431-85358624-B680-4B17-998B-040F7C9AC8A9Q35966191-E01A9DB7-4946-4C99-AD39-57EF21E321FCQ36035933-DB17DA4C-7917-4136-A76A-3ABD4D523AF2Q36057611-A3A456CB-BBCF-4960-A6B7-6E010C76C94AQ36084288-51FE1677-9C13-4723-BB82-9FD42BE253B4Q36214610-82E2550D-620E-4571-AA8B-6B23E3EC10ECQ36481165-F53513C9-EC35-4D67-9813-50E7F2E5A811
P2860
Therapeutic efficacy of ABT-737, a selective inhibitor of BCL-2, in small cell lung cancer
description
2008 nî lūn-bûn
@nan
2008 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2008 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
name
Therapeutic efficacy of ABT-73 ...... L-2, in small cell lung cancer
@ast
Therapeutic efficacy of ABT-73 ...... L-2, in small cell lung cancer
@en
Therapeutic efficacy of ABT-73 ...... -2, in small cell lung cancer.
@nl
type
label
Therapeutic efficacy of ABT-73 ...... L-2, in small cell lung cancer
@ast
Therapeutic efficacy of ABT-73 ...... L-2, in small cell lung cancer
@en
Therapeutic efficacy of ABT-73 ...... -2, in small cell lung cancer.
@nl
prefLabel
Therapeutic efficacy of ABT-73 ...... L-2, in small cell lung cancer
@ast
Therapeutic efficacy of ABT-73 ...... L-2, in small cell lung cancer
@en
Therapeutic efficacy of ABT-73 ...... -2, in small cell lung cancer.
@nl
P2093
P2860
P1433
P1476
Therapeutic efficacy of ABT-73 ...... L-2, in small cell lung cancer
@en
P2093
Christine L Hann
D Neil Watkins
Daniel L Wilburn
Elizabeth A Sugar
Irina Dobromilskaya
Jared S Hierman
Leslie Cope
Sara C Murphy
Vincent C Daniel
P2860
P304
P356
10.1158/0008-5472.CAN-07-5031
P407
P577
2008-04-01T00:00:00Z